Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Trial of Neoadjuvant MK-2206 in Combination With Either Anastrozole if Postmenopausal or Anastrozole and Goserelin if Premenopausal in Women With Clinical Stage 2 or 3 PIK3CA Mutant Estrogen Receptor Positive and HER2 Negative Invasive Breast Cancer

Trial Profile

A Phase II Trial of Neoadjuvant MK-2206 in Combination With Either Anastrozole if Postmenopausal or Anastrozole and Goserelin if Premenopausal in Women With Clinical Stage 2 or 3 PIK3CA Mutant Estrogen Receptor Positive and HER2 Negative Invasive Breast Cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 15 May 2018

At a glance

  • Drugs MK 2206 (Primary) ; Anastrozole; Goserelin
  • Indications Advanced breast cancer; Early breast cancer
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 06 Apr 2018 Status changed from active, no longer recruiting to discontinued as the study did not pass stage 1 interim analysis
    • 05 Sep 2017 Primary endpoint (Pathological complete response based on tumor Ki-67 value [ Time Frame: Up to day 17 of course 1 ]) has not been met as per the results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top